Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
---|
03/09/2011 | EP2292631A1 Regeneration of endogenous myocardial tissue by induction of neovascularization |
03/09/2011 | EP2292275A2 Protecting therapeutic compositions from host-mediated inactivation |
03/09/2011 | EP2292274A1 Compositions and methods for protein production |
03/09/2011 | EP2292250A1 Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline parvovirus and feline herpes virus |
03/09/2011 | EP2291520A1 Nucleic acid molecule and method of targeting gene expression to gliomas |
03/09/2011 | EP2291200A2 Methods for modulating expression of rbp4 |
03/09/2011 | EP1771570B1 Addition of transgenes into adenoviral vectors |
03/09/2011 | EP1758999B1 METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA |
03/09/2011 | EP1748069B1 Follistatin mutant polypeptide |
03/09/2011 | EP1276887B1 Protection against environmental toxicity through manipulation of the processing of messenger rna precursors |
03/09/2011 | EP1181320B1 Somatic transgene immunization and related methods |
03/09/2011 | CN101984056A RNA interference target RNA of long non-coding RNA related to human melanoma cells and application thereof |
03/08/2011 | USRE42211 Relating to binding proteins for recognition of DNA |
03/08/2011 | US7902441 Group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6 ,123F2 (RaSSFI), SEM A3 and Beta* (BLU), defined by homozygous deletion in lung cancer, have been located, isolated at 3p21.3 |
03/08/2011 | US7902348 Janus family kinases and identification of immune modulators |
03/08/2011 | US7902165 Inhibiting of the proliferation of tumor cells is mediated by upregulation of the activity of p53 |
03/08/2011 | US7902164 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
03/08/2011 | US7902160 ENA nucleic acid drugs modifying splicing in mRNA precursor |
03/08/2011 | US7902151 Methods and compositions for modulating immunity |
03/08/2011 | US7902149 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
03/08/2011 | US7901917 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
03/08/2011 | US7901898 Tuberculosis diagnostic test |
03/08/2011 | US7901706 Liposomes, micelles, polyelectrolytes; contact lenses; films; drug delivery; gene therapy |
03/08/2011 | US7901693 Compositions and methods for WT1 specific immunotherapy |
03/08/2011 | US7901683 Methods of inhibiting amyloid toxicity |
03/08/2011 | US7901671 Therapeutic retroviral vectors for gene therapy |
03/08/2011 | CA2498565C Composition for treating virus infection disease comprising jab1 |
03/08/2011 | CA2361251C Formulations comprising antisense nucleotides to connexins |
03/08/2011 | CA2329054C A novel polypeptide hormone phosphatonin |
03/08/2011 | CA2240516C Novel tyrosine kinase receptors and ligands |
03/03/2011 | WO2011025862A2 Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1 |
03/03/2011 | WO2011025556A1 Targeting pax2 for the treatment of breast cancer |
03/03/2011 | WO2011024918A1 Antiangiogenic agent and method for inhibition of angiogenesis |
03/03/2011 | WO2011024480A1 Drug composition for angiogenesis therapy |
03/03/2011 | WO2011024441A1 Ercc6l as target genes for cancer therapy and diagnosis |
03/03/2011 | WO2011024428A1 Breast cancer related gene c12orf32 |
03/03/2011 | WO2010123648A3 Compositions and methods for the treatment of sepsis and other disorders involving phospholipase a2 induction |
03/03/2011 | US20110055965 Cycle single-stranded nucleic acid complex and method for producing the same |
03/03/2011 | US20110055940 Therapeutic Inhibitors of PAI-1 Function Methods of Their Use |
03/03/2011 | US20110054160 Therapeutic compositions |
03/03/2011 | US20110054159 Rna interference mediating small rna molecules |
03/03/2011 | US20110054005 Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
03/03/2011 | US20110054003 Antisense oligonucleotide modulation of stat3 expression |
03/03/2011 | US20110053863 Methods of using flt3-ligand in the treatment of cancer |
03/03/2011 | US20110053860 COX-2 function and wound healing |
03/03/2011 | US20110053781 Methods and compositions for polypeptide engineering |
03/03/2011 | US20110053249 Adenoviruses Mutated In The VA Genes For Cancer Treatment |
03/03/2011 | US20110053182 Diagnosis of pre-cancerous conditions using pcdgf agents |
03/03/2011 | US20110052637 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as vaccines |
03/03/2011 | US20110052632 Hiv polynucleotides and polypeptides derived from botswana mj4 |
03/03/2011 | US20110052628 Recombinant Double-Stranded RNA Phage, and Use of the Same |
03/03/2011 | US20110052617 Aav scleroprotein, production and use thereof |
03/03/2011 | US20110052615 Tumour-specific animal proteins |
03/03/2011 | US20110052601 Compositions comprising anti-icam-1 antibodies |
03/03/2011 | US20110052588 Method of treating hepatocellular carcinoma |
03/03/2011 | US20110052584 Method of enhancement of cytotoxicity in antibody mediated immune responses |
03/03/2011 | US20110052577 Antibodies |
03/03/2011 | US20110052558 Materials and methods for prevention and treatment of rna viral diseases |
03/03/2011 | US20110052540 Non-Aggregating Virus Formulation |
03/03/2011 | CA2772036A1 Targeting pax2 for the treatment of breast cancer |
03/02/2011 | EP2290104A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
03/02/2011 | EP2290103A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
03/02/2011 | EP2290083A1 Conserved neisserial antigens |
03/02/2011 | EP2290079A2 Neurotrophic factors |
03/02/2011 | EP2290078A2 Immunostimulatory nucleic acids |
03/02/2011 | EP2290054A1 Alphavirus particles and methods for preparation |
03/02/2011 | EP2289910A2 Differential in tumour gene products and use of same |
03/02/2011 | EP2289537A1 PDGF for use in the treatment of central nervous system disorders |
03/02/2011 | EP2288387A1 Novel soluble cd83 polypeptides, formulations and methods of use |
03/02/2011 | EP2288359A1 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
03/02/2011 | EP2288261A2 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
03/02/2011 | EP1740699B1 Connexin 40 tissue specific gene mutations |
03/02/2011 | EP1436403B1 Use of the adenoviral e2 late promoter |
03/02/2011 | EP1363663B1 Nucleic acid mucosal immunization |
03/02/2011 | EP1185662B1 Dna vaccines for dogs |
03/02/2011 | CN1832965B Endothelial cell specific antibodies and uses thereof |
03/02/2011 | CN1748034B Improved expression element |
03/02/2011 | CN1714150B Genetic products differentially expressed in tumors and the use thereof |
03/02/2011 | CN1674935B Biofunctional composition containing CpG or oligo-/polynucleotide and toxin or enterotoxin |
03/02/2011 | CN1646157B Multiple and multivalent DNA vaccines in ovo |
03/01/2011 | US7897757 for treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes and any other disease, trait, or condition that is related to or will respond to the levels of PTP-1B in a cell or tissue |
03/01/2011 | US7897740 Secreted protein called 36P6D5 characteristic of tumors |
03/01/2011 | US7897583 an antisense compound that hybridizes with a nucleic acid molecule that expreses PTPRU ( protein tyrosine phosphatase receptor type U), thereby inhibiting the expression of the nucleic acid molecule; treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia etc. |
03/01/2011 | US7897581 Methods and compounds for promoting vessel regression |
03/01/2011 | US7897562 Apoptosis-inducing agent and method for inducing apoptosis |
03/01/2011 | US7897384 Chondrocyte therapeutic delivery system |
03/01/2011 | US7897380 Circular nucleic acid vectors, and methods for making and using the same |
03/01/2011 | US7897346 Polyamide nucleic acid derivatives and agents, and processes for preparing them |
03/01/2011 | US7897158 Recombinant toxin fragments |
03/01/2011 | US7897151 Anti-IgE vaccines |
03/01/2011 | CA2677068A1 Nucleic acid compounds for inhibiting gene expression and uses thereof |
03/01/2011 | CA2348954C A pharmaceutical composition for treating immune diseases |
03/01/2011 | CA2339331C Expression and export of angiogenesis inhibitors as immunofusins |
03/01/2011 | CA2323525C Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
02/24/2011 | WO2011022606A2 Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
02/24/2011 | WO2011022427A1 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
02/24/2011 | WO2011021916A2 Use of egf-like domain of heregulin beta 1 peptide |
02/24/2011 | WO2011021508A1 Marker for predicting therapeutic effect on hepatitis c, method for predicting therapeutic effect on hepatitis c, and prophylaxis or therapeutic agent for hepatitis c |
02/24/2011 | WO2011020188A1 Peptide sequences and peptide-mediated sirna delivery |
02/24/2011 | WO2010148065A9 Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |